China Medical University Hospital

China Medical University

Shine-on Biomedical Co., Ltd.

Der-Yang Cho

Shao-Chih Chiu

Shi-Wei Huang

Chih-Ming Pan

Yeh Chen

Mei-Chih Chen

Yu-Chuan Lin

Chia-Ing Jan

Yi-Wen Chen

Woei-Cherng Shyu

Wei Lee

San-Yuan Chen

Chang-Hai Tsai

Chen-Huan Lin

Chung-Y Hsu

Long-Bin Jeng

Chao-Jung Chen

Ming-You Shie

Kai-Wen Kan

Jiaxin Yu

Kai-Ching Chen

Chien-Chang Chen

Po-Ren Hsueh

Chih-Yu Chi

Tien Ni

Chia-Huei Chou

Yow-Wen Hsieh

Ni Tien

Pei-Ran Sun

Lu-Ching Ho

Ming-Tung Chen

Kai-Cheng Hsu

Jia-Xin Yu

Ya-Lun Wu

Hsin-Yuan Fang

Min-Hua Yu

Cheng-Yu Chen

The present disclosure provides an anti-specific antibody and the nucleic acid encoding sequence thereof, and uses of the same. The anti-specific antibody of the present disclosure achieves the effect of treatinginfection and enhancing immune cells againstthrough various efficacy experiments.

Anti-specific antibody and nucleic acid encoding sequence thereof, and uses of the same

An intelligent medical speech automatic recognition method includes performing a first model training step, a second model training step, a voice receiving step, a signal pre-treatment step and a transforming step. The first model training step is performed to train a generic statement data and a medical statement data of a database to establish a first model. The second model training step is performed to train a medical textbook data of the database to establish a second model. The voice receiving step is performed to receive a speech signal. The signal pre-treatment step is performed to receive the speech signal from the voice receiver and transform the speech signal into a to-be-recognized speech signal. The transforming step is performed to transform and recognize the to-be-recognized speech signal into a complete sentence writing character according to the first model and the second model.

Intelligent medical speech automatic recognition method and system thereof

The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same

Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Tumor microenvironment on chip

Display screen or portion thereof with graphical user interface

The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 &#x3b5;.

Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

Disclosed is a method for identifying methicillin-resistantthrough detection a mass signal at m/z of 6580-6600 in the MALDI-TOF mass spectrum. Also disclosed is a novel peptide biomarker, which consists of SEQ NO ID:5 and the use thereof for detection and/or identification of methicillin-resistant

Method of identification of methicillin-resistant

A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).

Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue

A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Methods for treating a brain tissue damage by cultured adult pluripotent olfactory stem cells

A method of evaluating if a glioblastoma multiforme (GBM) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the GBM patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the GBM patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the GBM patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the GBM patient is determined to have a good prognosis after the treatment when the expression level of the sample from the GBM is lower than the threshold.

Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment

Growing community of inventors

Taichung, Taiwan

Der-Yang Cho